National Impact

Sovereign impact metrics.

What a domestic supply chain returns: access, resilience, and a high-skill economy.

Projected GDP Contribution
0
By 2040
Contribution to national biotech GDP
High-Skill Jobs
0
Employment pipeline
Direct and indirect, through 2030
Sovereign Capacity
0
Installed bioreactor volume
Vaccine Self-Sufficiency
0
End-to-end localization target
Pipeline
0
Molecules in development
Markets
0
Territories supplied
Facilities
0
GMP sites, one quality system
Mandate Alignment

Three mandates, one site.

National health security, regional industrial capability and global immunisation equity are usually pursued by three different institutions. Adjuvant Bio was built where they overlap, which is what makes the capital case work.

Strategic Alignment

Three returns on sovereign supply.

Health security

Essential medicines that cannot be cut off at a border during a crisis.

Economic diversification

High-value manufacturing and a research base that compounds over time.

Talent & knowledge

A generation of scientists and operators trained on a world-class platform.

Active Programs

Strategic initiatives.

Preparedness

Pandemic response reserve

Standing capacity held in reserve for rapid conversion to outbreak response, validated and audit-ready.

  • 100-day response readiness
  • Multi-modality platform
  • Pre-negotiated supply agreements
Workforce

Biotech talent accelerator

A training pipeline that turns graduates into GMP-ready process scientists and operators.

  • Sterile-operations programme
  • University research partnerships
  • Apprenticeship to leadership tracks

See the pipeline behind the numbers.

Every metric here traces back to programmes in development.